Boston Scientific Corporation $BSX Shares Acquired by Rathbones Group PLC

Rathbones Group PLC increased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 20.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,759,657 shares of the medical equipment provider’s stock after buying an additional 477,680 shares during the quarter. Boston Scientific comprises approximately 0.8% of Rathbones Group PLC’s portfolio, making the stock its 24th largest position. Rathbones Group PLC’s holdings in Boston Scientific were worth $263,133,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the business. Steph & Co. purchased a new position in Boston Scientific during the third quarter worth about $25,000. Financial Consulate Inc. purchased a new stake in shares of Boston Scientific in the 3rd quarter valued at approximately $25,000. Murphy & Mullick Capital Management Corp raised its stake in shares of Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 170 shares during the period. FWL Investment Management LLC acquired a new position in shares of Boston Scientific in the 2nd quarter worth approximately $26,000. Finally, United Community Bank lifted its holdings in shares of Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 147 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

BSX has been the subject of several research reports. National Bank Financial set a $115.00 target price on shares of Boston Scientific in a report on Monday, February 2nd. Canaccord Genuity Group lowered their price target on Boston Scientific from $112.00 to $109.00 and set a “buy” rating for the company in a research report on Tuesday, February 17th. Barclays dropped their price objective on Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a research note on Tuesday, February 3rd. Citigroup cut their price objective on Boston Scientific from $102.00 to $94.00 and set a “buy” rating on the stock in a report on Wednesday, March 11th. Finally, Robert W. Baird decreased their target price on Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $104.36.

Insider Activity at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Stock Down 0.1%

Boston Scientific stock opened at $62.73 on Monday. The firm has a market capitalization of $93.23 billion, a P/E ratio of 32.34, a P/E/G ratio of 0.97 and a beta of 0.78. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. Boston Scientific Corporation has a twelve month low of $61.24 and a twelve month high of $109.50. The stock’s fifty day simple moving average is $74.61 and its 200-day simple moving average is $89.26.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same period last year, the business posted $0.70 earnings per share. Boston Scientific’s revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.